Abstract:Background: A proportion of prostate cancers (PCa) are hereditary, driven by likely pathogenic/pathogenic germline variants (PGVs) in DNA repair genes. PGVs in BRCA2 contribute to aggressive prostate cancer biology and overall poorer survival. Genetic testing and targeted sequencing panels help identify PGV carriers who are susceptible to aggressive PCa and may be candidates for targeted therapy with PARP inhibitors. Prior research suggested a high rate of 10-20% of metastatic PCa (mPCa) patients have PGVs in DNA repair genes; however, many of these studies reported highly selected research cohorts. The real-world rate of DNA repair PGVs and whether any genotype-phenotype correlations exist in broader, more racially diverse clinical populations are not well understood. Patients and Methods: We studied two prospective cohorts of males with PCa who presented for genetic testing due to meeting NCCN personal history genetic testing criteria for prostate cancer (metastatic or high risk/very high risk localized). We report PGV frequencies of mPCa patients who underwent genetic testing in a point of care model at the Basser Center within Penn Medicine (Penn-POC, n=596), and a cancer genetics practice at the Corporal Michael Crescenz VA Medical Center in Philadelphia (VA-GT, n = 171). PGVs were identified in ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PMS2, TP53. Results: The Penn-POC and VA-GT cohort included 437 (73.3%) and 59 (34.5%) self-identified white patients, respectively, and 121 (20.3%) and 107 (62.6%) self-identified black patients, respectively. In the Penn-POC and VA-GT cohorts, 7.2% and 7.6% patients were found to carry a PGV, respectively, and 11.9% and 18.1% of patients had variants of uncertain significance (VUS), respectively. The most common PGVs in the Penn-POC cohort were in BRCA2 (2.2%), ATM (1.9%), and BRCA1 (1.3%). The most common PGVs in the VA-GT cohort were in BRCA2 (2.9%), ATM (1.1%), and CHEK2 (1.2%). PGV rates were not statistically different between self-identified white and black patients in either cohort (Penn-POC p= 0.4036; VA-GT p=0. 0.4061). Overall PGV frequencies between the Penn-POC and VA-GT cohorts are not statistically different. There is a correlation between carrier status and age at diagnosis with a significant difference between carriers and non-carriers (p=0.0433) as well as with family history of first degree relatives with PCa (p=0.0184). However, there was not a significant correlation between carrier status and clinical stage at diagnosis, Gleason grade group, or other clinical variables. Conclusions: We report a lower rate of DNA repair PGVs in two prospectively ascertained, racially diverse cohorts of mPCa patients, approximately 7%, compared to the previously reported rates of 10-20%. Our results suggest age and family history, but not other pathological variables are clinical predictors for carrying a PGV in mPCa patients. Citation Format: Taylor Crawford, Emanuel Barrett, Tara Al-Saleem, Maliha Tayeb, Heather Symecko, Caitlin Orr, Vivek Narayan, Samuel Takvorian, Ravi B. Parikh, Yu-Ning Wong, Kyle Robinson, Lisa B. Aiello, Catherine Wolfe, Derek Mann, Kelsey Spielman, Susan M. Domchek, Kara N. Maxwell. Clinical genetic testing results in metastatic prostate cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3372.

Real-world genomic testing patterns in patients with prostate cancer.

Current Practices in Genetic Testing for Prostate Cancer: The Indian Scenario

Abstract 3372: Clinical genetic testing results in metastatic prostate cancer patients

Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing

Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer

Homologous recombination repair gene mutation (HRRm) testing patterns and treatment selection from a real-world cohort of patients with metastatic castration-resistant prostate cancer (mCRPC).

Prostate cancer genotyping for risk stratification and precision treatment

A prospective study of comprehensive genomic testing to identify actionable variants in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Testing BRCA 1-2 mutations in metastatic prostate cancer: results of a survey of the Italian Association of Medical Oncology

Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing

Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer

Clinical impact of mutations in driver oncogenes and TP53/RB1 in advanced prostate cancer.

Safety and clinical validity of tumor genomic testing for guiding active surveillance selection in men with NCCN intermediate-risk prostate cancer.

Genetic testing for hereditary prostate cancer: Current status and limitations

Patterns and Frequency of Pathogenic Germline Variants Among Prostate Cancer Patients Utilizing Multi-Gene Panel Genetic Testing

Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer

Geographical impact on prostate cancer genetic testing eligibility: A preliminary study from an academic cancer center.

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019

Integrative Clinical Genomics of Advanced Prostate Cancer

A cohort study evaluating the clinical, environmental and genetic profiles of men with early-onset, aggressive prostate cancer.

Impact of pharmaceutical excipients on in vitro association of saquinavir to chylomicrons.